# Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

> **NCT03564873** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 28 (actual)

## Conditions studied

- High Grade Myelodysplastic Syndromes

## Interventions

- **DRUG:** Omacetaxine
- **DRUG:** Azacitidine
- **DRUG:** Omacetaxine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03564873
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-17
- **Primary completion:** 2025-10-07
- **Final completion:** 2027-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564873, "Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT03564873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*